期刊文献+

重组人组织型纤溶酶原激活剂突变体基因的克隆、表达与生物活性鉴定 被引量:4

Cloning,Expression and Identification of Activity of Recombinant Tissue-type Plasminogen Activator Mutant
下载PDF
导出
摘要 目的 :研究重组人组织型纤溶酶原激剂突变体 (reteplase,r -PA)基因的克隆和表达 ,并对表达产物进行活性鉴定。方法 :通过PCR的方法从t-PA基因上扩增得到r-PA基因的编码序列 ,并克隆到pUC19载体中 ,经DNA测序正确后 ,将该基因克隆到含有T7启动子的高效表达质粒pJZ - 10 0中 ,转化E .coliBL2 1(DE3) ,得到含有r-PA基因的工程菌。工程菌经IPTG诱导表达 ,SDS -PAGE检测表达情况。提取包涵体 ,经过体外稀释法复性 ,亲和色谱层析纯化 ,测定产物的活性。结果 :表达的重组蛋白约占可溶性总蛋白的 2 0 % ,复性并纯化后测定活性为 5 80 0 0IU mg。结论 :成功构建了重组r-PA的表达质粒 ,表达产物具有良好的生物活性。 Objective:Study on cloning and expression of recombinant tissue-type plasminogen activator mutant.Identify the activity of recombinant protein.Method:Amplification r-PA coding sequence from human t-PA gene and then cloned it into pUC19 vector.The sequence is identical with which reported.This sequence is cloned into pJZ-100 expression vector which includes T7 promoter.Being induced by IPTG,reteplase were expressed in E.coli BL21(DE3).The result of expression was identified by SDS-PAGE.The inclusion boby refold by dilution in vitro.The protein of renaturation was purified by affinity chromatograph.Results:Expressed reteplase were above 20% of total bacterial protein.After renaturation and purification,reteplase specific activity was 580000IU/mg.Conclusion:An expression plasmid for reteplase was successfully constructed.The recombinant protein showes effective fibrinolysis.
出处 《生物技术》 CAS CSCD 2004年第5期6-8,共3页 Biotechnology
关键词 重组人组织型纤溶酶原激活剂突变体 克隆 表达 生物活性 reteplase cloning expression activity
  • 相关文献

参考文献8

  • 1The GUSTO investigators.Repeffusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein Ⅱb/Ⅱa inhibition:the GUSTO V randomised trial[J].Lancet,2001,357:1905-1914.
  • 2Lincoff AM,Califf RM,Van de Werf F,et al.Mortality at 1 year with combination platelet glycoprotein Ⅱb/Ⅲa inhibition and reduced-dose fibrinnolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial[J]
  • 3Wooster MB,Luzier AB.Reteplase:a new thrombolytic for the treatment of acute myocandial infarction[J].The Annals of Pharmcotherapy,1999,33:318-324.
  • 4Pennica D,Holmes WE,Kohr WJ,et al.Cloning and expression of human tissue-type plasminogen activator cDNA in E.coli[J].Nature,1983,301:214-221.
  • 5Kohnert U,Rudolph R,Verheijen JH,et al.Biochemical properties of the kringle 2 and pnotease domains are maintained in the refolded t-PA deletion variant BM 06.022[J].Protein Engineering,1992,5:93-100.
  • 6Heussen C,Joubert F,and Dowdle EB.Purification of human tissue plasminogen activator with erythrina trypsin inhibitor[ J].The Journal of Biological Chemistry,1984,259(19): 11635-11638.
  • 7黄震华,徐济民.新型溶栓药物瑞替普酶[J].中国新药杂志,1999,8(5):306-308. 被引量:34
  • 8刘晓宇,王憬惺.Reteplase—第3代基因重组纤溶酶原激活物[J].中国输血杂志,2000,13(2):127-130. 被引量:12

二级参考文献10

  • 1Martin U,Bader R,Bohm E,et al.BM06. 022: a novel recombinant plasminogen activator[].Cardiovascular Drugs.1993
  • 2INJECT Study Group.Retevase, Reteplase, recombinant.Physicians Desk Reference, Gaithersburg[].Medical Economics.1998
  • 3Kanamasa K,Watanabe I,Cercek B,et al.Selective decrease in lysis of old thrombi offers rapid administration of tissue type plasminogen activator[].Journal of the American College of Cardiology.1989
  • 4Martin U,von Mollendorff E,Akpan W.Pharmacokinetic and hemostatic properties of the recombinant plasminogen activator BM 06. 022 in healthy volunteers[].Thrombosis and Haemostasis.1991
  • 5Martin U,Dalchau H,Sponer G,et al.Effects of the novel recombinant plasminogen activator BM 06. 022 on platelets and bleeding time in rabbits[].Platelets.1992
  • 6Smalling RW,Bode C,Kalbfleisch J,et al.More rapid, complete, and stable coronary thrombolysis with bolus administration of Reteplase compared with Alteplase infusion in AMI[].Circulation.1995
  • 7Versraete M.Lijnen H, Collen D.Thromblytics agents in development[].Drugs.1995
  • 8Martin U & von Mollendorff E.Dose-ranging study of the novel recombinant plasminogen activator BM 06. 022 in healthy volunteers[].Clinical Pharmacology and Therapeutics.1991
  • 9INJECT Study Group.Randomized, double-blind comparison of Reteplase double-bolus administration with streptokinase in actue myocardial infarction trial to investigate equivalence[].The Lancet.1995
  • 10Martin U,Fischer S,Konert U,et al.Coronary thrombolytics properties of novel recombinant plasminogen activator BM 06. 022 in canine model[].J Cardiovasc Pharmacol.1991

共引文献44

同被引文献51

引证文献4

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部